Last edition
News about "biopharmaceutical company "
OncoC4 Doses First Patient in Phase 1 Trial of ONC-783 T-Cell Engager
OncoC4 has dosed the first patient in its Phase 1 ONC-783-001 trial, evaluating the investigational T-cell engager ONC-783, developed to target the cancer-specific neoCD24 epitope in patients with advanced solid tumours.
Biopharmaceutical Company | 18/08/2026 | By News Bureau
Acurx Pharmaceuticals Secures FDA Conditional Acceptance of Cifbezy Name for Ibezapolstat
Acurx Pharmaceuticals has secured FDA conditional acceptance of Cifbezy as the proposed brand name for ibezapolstat and received USPTO trademark allowance, marking key preparatory milestones ahead of planned international Phase 3 development for C. difficile infection.
Biopharmaceutical Company | 18/08/2026 | By News Bureau
Tris Pharma Partners with Calm Health, ADHD Central to Expand Support for ADHD Patients
Tris Pharma has partnered with Calm Health and ADHD Central to complement ADHD treatment with mental wellness, organisation and productivity resources for patients and caregivers.
Biopharmaceutical Company | 14/08/2026 | By News Bureau
Supernus and Indivior to Merge in All-Stock Deal to Create Diversified CNS Biopharma Leader
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction, creating a diversified CNS-focused biopharmaceutical company with 11 marketed therapies, projected annual revenue of USD 2.2 billion and expanded capabilities in psychiatry, neurology and addiction treatment.
Biopharmaceutical Company | 04/08/2026 | By News Bureau
Estrella Doses First Patient in EB103 Dose-Expansion Trial for Relapsed/Refractory B-Cell NHL
Estrella Immunopharma advances its STARLIGHT-1 Phase I/II trial with the first patient dosed in the EB103 dose-expansion cohort, building on promising early efficacy in relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Biopharmaceutical Company | 28/07/2026 | By News Bureau
Chiesi Secures UK Approval for World's First Low-Carbon pMDIs Using Next-Generation Propellant
MHRA authorises Clenil Modulite inhalers with a non-PFAS, low global warming potential propellant, reducing carbon emissions by up to 90 percent while maintaining therapeutic efficacy.
Biopharmaceutical Company | 23/07/2026 | By News Bureau
JCR Pharmaceuticals secures its first international approval for Izcargo in the UAE, expanding access to its innovative blood-brain barrier-penetrating therapy for patients with Hunter syndrome and advancing rare disease treatment across the MENA region.
Biopharmaceutical Company | 23/07/2026 | By News Bureau | 100
TolerogenixX Secures EU Orphan Drug Designation for MIC-Lx in Living-Donor Kidney Transplantation
European Commission grants orphan status to Tolerogenix’s personalized cell therapy following EMA recommendation, strengthening its regulatory pathway alongside recent PRIME designation.
Biopharmaceutical Company | 14/07/2026 | By News Bureau
New patient-derived xenograft study demonstrates strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, paving the way for expanded clinical evaluation in Phase 1/2a trials.
Biopharmaceutical Company | 09/07/2026 | By News Bureau | 100
Sanyou Bio, Baiyunshan Xihe Partner to Advance AI-Driven Radiopharmaceutical Development
Sanyou Biopharmaceuticals and Guangzhou Baiyunshan Xihe Health Pharmaceutical have entered a strategic partnership to co-develop innovative radiopharmaceuticals and radiodiagnostic products.
Biopharmaceutical Company | 07/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy